European Parliament
2014-2019

Plenary sitting

B8-0008/2017

22.12.2016

MOTION FOR A RESOLUTION

pursuant to Rule 133 of the Rules of Procedure

on Duchenne muscular dystrophy

Mireille D'Ornano

B8-0008/2017

Motion for a European Parliament resolution on Duchenne muscular dystrophy

The European Parliament,

– having regard to Article 168 of the Treaty on the Functioning of the European Union,

– having regard to Rule 133 of its Rules of Procedure,

A. whereas Duchenne muscular dystrophy (DMD) is a type of genetic muscular dystrophy caused by a mutation, resulting in a shortage of dystrophin in the DMD gene, and whereas it has an incidence of about 1 in 4 000; whereas this disease leads to fatal paralysis in sufferers, whose average life expectancy is 25;

B. whereas a treatment recently developed by PTC Therapeutics International Limited was granted a provisional marketing authorisation for the EU on 31 July 2014, but whereas this product is difficult to obtain and barely affordable for European patients;

1. Urges the Commission and the European Medicines Agency to facilitate further renewals of authorisation for the drug concerned, Translarna, within the EU and to do their utmost to make it as affordable as possible;

2. Urges the Member States and their health authorities to take the steps required to ensure that Translarna is as inexpensively priced and as widely available as possible under public health systems.